I think we need Sandpuppy to read this and comment. I am not advocating for the late use of HCQ, and indeed many trials have seemingly been designed to fail in this way. I do though think this is interesting because it counters the VA study. Here is the link;
https://www.medrxiv.org/content/10.1101/2020.04.27.20073379v1Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19
Bo Yu, Dao Wen Wang, Chenze Lidoi: https://doi.org/10.1101/2020.04.27.20073379
RESULTS: The median age of 568 critically ill patients is 68 (57, 76) years old with 37.0% being female. Mortalities are 18.8% (9/48) in HCQ group and 45.8% (238/520) in NHCQ group (p<0.001). The time of hospital stay before patient death is 15 (10-21) days and 8 (4 - 14) days for the HCQ and NHCQ groups, respectively (p<0.05). The level of inflammatory cytokine IL-6 was significantly lowered from 22.2 (8.3-118.9) pg/mL at the beginning of the treatment to 5.2 (3.0-23.4) pg/ml (p<0.05) at the end of the treatment in the HCQ group but here is no change in the NHCQ group. CONCLUSIONS AND RELEVANCE: Hydroxychloroquine treatment is significantly associated with a decreased mortality in critically ill patients with COVID-19 through attenuation of inflammatory cytokine storm. Therefore, hydroxychloroquine should be prescribed for treatment of critically ill COVID-19 patients to save lives.
The baseline treatments were comparable for these two groups, including application of antiviral drugs (Lopinavir and Ritonavir, Entecavir hydrate, or Ribavirin) with 41.7% and 44.4% patients in HCQ and NHCQ, respectively, (p=0.71); intravenous immunoglobulin in 52.1% in HCQ and 47.1% patients in NHCQ, respectively (p=0.51); immunoenhancer in 16.7% in HCQ and 17.3% patients in NHCQ, respectively (p=0.91), but antibiotics in 77.1% in HCQ and 89.4% patients in NHCQ, respectively (p=0.01); but interferon application 0% in HCQ and 10.4% patients in NCHQ (p=0.01).